Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02703571
Recruitment Status : Active, not recruiting
First Posted : March 9, 2016
Last Update Posted : July 10, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.

Condition or disease Intervention/treatment Phase
Solid Tumors Pancreatic Cancer Colorectal Cancer Drug: ribociclib Drug: Trametinib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
Actual Study Start Date : June 29, 2016
Estimated Primary Completion Date : September 4, 2019
Estimated Study Completion Date : September 4, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Advanced or metastatic pancreatic cancer
Patients in the Phase II portion of the study who have advanced or metastatic pancreatic cancer
Drug: ribociclib
Other Name: LEE011

Drug: Trametinib
Other Name: TMT212

Experimental: KRAS-mutant colorectal cancer
Patients in the Phase II portion of the study who have KRAS-mutant colorectal cancer
Drug: ribociclib
Other Name: LEE011

Drug: Trametinib
Other Name: TMT212




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities (DLTs) [ Time Frame: 21-day cycle one of treatment ]

    Phase I part:

    The primary variable is the incidence of DLTs during the first 21 days of therapy. Estimation of the MTD of the combination treatment will be based upon the estimation of the probability of DLT during the first 21 days of therapy for patients in the DDS.


  2. Objective Response Rate (ORR) [ Time Frame: Until progression of disease up to 1 year ]

    Phase II part:

    The primary variable used to evaluate the efficacy of the ribociclib and trametinib combination is the ORR, defined as the proportion of patients with a best overall confirmed CR or PR, as assessed per RECIST 1.1 by investigator assessment.



Secondary Outcome Measures :
  1. Duration of response (DOR) [ Time Frame: Until progression of disease up to 1 year ]
    Among patients with a confirmed response (PR or CR) per RECIST 1.1, DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause. The distribution function of DOR will be estimated using the Kaplan-Meier method. The median DOR along with 95% CI will be presented by treatment arm.

  2. Time to response [ Time Frame: Until progression of disease up to 1 year ]
    Time to overall response of CR or PR (TTR) is defined as the time from start of study drug to first documented response (CR or PR, which must be confirmed subsequently) for patients with a confirmed CR or PR. TTR will be summarized by treatment arm, using descriptive statistics.

  3. Disease control rate [ Time Frame: Until progression of disease up to 1 year ]
    Disease control rate (DCR) is defined as the proportion of patients with best overall response of CR, PR, or SD per RECIST 1.1. DCR will be estimated and the binomial exact 95% CI will be provided by arm.

  4. Progression disease rate [ Time Frame: Until progression of disease up to 1 year ]
    Progression disease rate defined as the proportion of patients with a progression disease as assessed per RECIST 1.1 by investigator assessment.

  5. Progression free survival [ Time Frame: Until progression of disease up to 1 year ]
    Progression-free survival (PFS) is defined as the time from the date of the first dose of study drug to the date of first documented disease progression per RECIST 1.1 or death due to any cause.

  6. overall survival [ Time Frame: Until death up to 1 year ]
    Overall survival (OS) is defined as the time from the date of first dose of study drug to the date of death due to any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (All):

  • Written informed consent must
  • Patient has histologically and/or cytologically confirmed malignancies:

Phase I:

• Patients with advanced or metastatic solid tumors who have failed at least one prior line of systemic antineoplastic therapy in the advanced setting without a standard of care treatment option available;

Phase II:

  • Advanced or metastatic pancreatic adenocarcinoma who have failed at least one prior systemic antineoplastic therapies in the advanced setting
  • Advanced or metastatic KRAS-mutant CRC who have failed at least two prior systemic antineoplastic therapies in the advanced setting without a standard of care treatment option available. Testing for KRAS mutation in patients with CRC using locally approved diagnostic kit will be used for eligibility.
  • Phase II only: patient must have measurable disease
  • Patient has an ECOG performance status 0 or 1.
  • Patient has adequate bone marrow and organ function
  • Patient must have specified laboratory values within normal limits or corrected to within normal limits with supplements before the first dose of study medication on Cycle 1 Day 1:
  • Standard 12-lead ECG values defined

Exclusion Criteria:

Phase II only:

• Patient has received prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.

Phase I and Phase II:

  • Patient with a known hypersensitivity to the study drugs or any of the excipients of ribociclib or trametinib.
  • Patient is concurrently using other anti-cancer therapy.
  • Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to Cycle 1 Day 1
  • Patient has received local therapy to liver ≤ 3 months of C1D1
  • History of liver disease as follow:
  • Cirrhosis
  • Autoimmune hepatitis
  • Active viral hepatitis
  • Portal hypertension
  • Drug induced liver steatosis
  • Prior systemic anti-cancer treatment within 28 days prior to Cycle 1 Day 1
  • Prior therapy with anthracyclines at cumulative doses of 450 mg/ m2 or more for doxorubicin or 900 mg/m2 or more for epirubicin.
  • Patient is currently receiving warfarin or other coumadin derived anti-coagulant
  • Patient has a history of deep venin thrombosis or pulmonary embolism within 6 months of screening.
  • Patient has a concurrent malignancy or malignancy within 3 years prior to Cycle 1 Day 1, with the exception of adequately treated basal or squamous cell carcinoma or curatively resected cervical cancer.
  • Patients with central nervous system (CNS) involvement
  • Patient has impairment of GI function or GI disease that may significantly alter the absorption of the study drugs
  • History of interstitial lung disease or pneumonitis.
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
  • Patient is currently receiving any strong inducers or inhibitors of CYP3A4/5 and/or Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 and cannot be discontinued 7 days prior to Cycle 1 Day 1:
  • Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment.
  • History of retinal vein occlusion (RVO)

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02703571


Locations
Layout table for location information
United States, Arkansas
Highlands Oncology Group
Fayetteville, Arkansas, United States, 72703
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
United States, Florida
University of Miami Sylvester Comp Cancer Ctr
Miami, Florida, United States, 33136
United States, Massachusetts
Dana Farber Cancer Center
Boston, Massachusetts, United States, 02215
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Australia, Victoria
Novartis Investigative Site
Melbourne, Victoria, Australia, 3000
Belgium
Novartis Investigative Site
Leuven, Belgium, 3000
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 4E6
Germany
Novartis Investigative Site
Koeln, Germany, 50937
Novartis Investigative Site
Ulm, Germany, 89081
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1066 CX
Novartis Investigative Site
Utrecht, Netherlands, 3584 CX
Spain
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02703571     History of Changes
Other Study ID Numbers: CTMT212X2106
2015-005019-34 ( EudraCT Number )
First Posted: March 9, 2016    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Trametinib
Ribociclib
LEE011
TMT212
advanced solid tumors
pancreatic cancer
KRAS-mutant colorectal cancer
colorectal cancer
advanced pancreatic cancer
metastatic pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Pancreatic Neoplasms
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Trametinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action